Retatrutide Skin Sensitivity (Dysesthesia): Why It Happens and What Helps

Retatrutide skin sensitivity is common and usually mild. In Lilly's six Phase 3 trials, 2.3% to 20.9% of people on the drug reported skin that burns, tingles or hurts to the touch (dysesthesia). In the five placebo-controlled trials, 1.3% or fewer on placebo did, and in the head-to-head trial 2.7% of people on Ozempic 2 mg did. The top figure, about 1 in 5 people, came on 12 mg in TRIUMPH-4. Lilly calls the cases generally mild or mild to moderate, and for five of the six trials it says the majority resolved during treatment. Why it happens hasn't been published.

This page collects the retatrutide skin numbers from Lilly's releases, the published papers and the Phase 2 trial registry, as of October 2026, including the Oct 28 head-to-head result against Ozempic. Where that data runs out, we use the FDA labels for semaglutide and tirzepatide, which is class evidence, not retatrutide data. The full list of effects is in our guide to retatrutide side effects.

What retatrutide skin sensitivity feels like

Dysesthesia is the umbrella word for skin that feels wrong without looking wrong: burning, tingling, pins and needles, or pain from a touch that shouldn't hurt, like a shirt seam or a bedsheet. Lilly's releases use the single word and don't say which symptoms they counted under it. The Wegovy label does spell out its grouping for semaglutide, and it's broad. It counts paresthesia (pins and needles), hyperesthesia (skin that overreacts to touch), allodynia (pain from light touch), burning skin, pain of skin and sensitive skin, among others.

Retatrutide's Phase 2 obesity trial reported the pieces separately. ClinicalTrials.gov lists every side effect that reached 5% of any group during up to 52 weeks of follow-up. Three skin-sensation terms made that list, along with itching and rash:

Allodynia, the version where ordinary touch hurts, showed up only in the 12 mg group: 4 of 62 people (6.5%). The placebo group had one case of hyperaesthesia, a reminder that odd skin sensations happen without any drug. Groups this small can't give reliable rates.

No trial has measured how much the sensation costs people in sleep or comfort. If it's keeping you awake, see retatrutide insomnia.

How common is retatrutide skin sensitivity?

Every Phase 3 readout from Lilly lists dysesthesia above its comparator. Here are all six trials, ordered by weight lost on 12 mg.

Weight loss is Lilly's efficacy estimand, the result if everyone had stayed on treatment. "Extra cases" is our subtraction: the 12 mg rate minus the comparator's. As of October 2026, TRIUMPH-1 (NEJM), TRIUMPH-2 (The Lancet) and TRANSCEND-T2D-1 (The Lancet) have journal papers; TRIUMPH-3, TRIUMPH-4 and TRANSCEND-T2D-2 don't. The TRIUMPH-2 paper confirms the Lilly figures with counts: 21 of 287 people on 12 mg had dysesthesia against 2 of 289 on placebo.

About 1 in 5 people on 12 mg in TRIUMPH-4 (20.9%) and about 1 in 8 in TRIUMPH-1 (12.5%) reported it.

Two patterns show up. The rate usually rises with dose, from 5.1% on 4 mg to 12.5% on 12 mg in TRIUMPH-1, though TRIUMPH-3 is flat between 9 and 12 mg and TRANSCEND-T2D-1 breaks the pattern. And the trials in people with type 2 diabetes sit lower, at 7.3% or less on 12 mg. Those trials also produced less weight loss, and TRANSCEND-T2D-1 ran only 40 weeks, so more than one explanation fits.

The head-to-head trial adds a useful yardstick. On Ozempic 2 mg, the highest approved semaglutide dose for diabetes, 2.7% of people had dysesthesia, more than any placebo group in the other five trials. Retatrutide 12 mg was 6.5%. The trial was open-label, so people knew which drug they were on. Stomach side effects from the same trial are in our side effects guide.

You may have seen "about 7%" quoted as the rate. We couldn't trace it to a primary source, and with the 12 mg rate running from 4.4% to 20.9%, one number hides most of the story.

Why does reta make your skin sensitive?

Nobody knows. Lilly hasn't published a mechanism, and no study has examined the nerves or skin of people taking retatrutide. The obvious suspect is the glucagon receptor, since that's what retatrutide adds on top of tirzepatide. The approved drugs make that theory hard to hold.

Semaglutide has no glucagon action, yet 22% of people on the 7.2 mg dose reported dysesthesia, against 6% on 2.4 mg in the same trials. That's class evidence from different trials, so treat the comparison as rough. In the one trial that put the two drugs side by side, retatrutide ran higher than semaglutide (6.5% on 12 mg vs 2.7% on Ozempic 2 mg), but that dose of semaglutide is far below 7.2 mg. The Wegovy label adds that dysesthesia with semaglutide increased with dose and with drug levels in the blood.

Our read: the glucagon receptor can't be the whole story, because semaglutide doesn't act on it and still reached 22% at 7.2 mg. Dose and drug level look like the better lead, since retatrutide's rates also climbed with dose in most of its trials.

When it starts and how long it lasts

No retatrutide release says when dysesthesia starts or how long a typical case lasts. What the trials do show is a schedule that raises the dose every 4 weeks, and skin rates that climb with dose in most of them. If skin symptoms follow drug levels, as the Wegovy label says they do for semaglutide, the weeks after each step up are the likely window.

On duration, Lilly says the majority of cases resolved during treatment in TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRANSCEND-T2D-1 and TRANSCEND-T2D-2, and for TRIUMPH-1 it added that most people kept taking the drug. For TRIUMPH-4 it said only that cases were generally mild and rarely led anyone to stop. "The majority" still leaves a minority. The semaglutide label puts a number on it: 18% of people with dysesthesia on 7.2 mg hadn't recovered by the end of the trial, and most of them had stayed on the same dose.

Relief isn't instant, because retatrutide's half-life is about 6 days, according to the Phase 1b trial in The Lancet. Any dose change takes weeks to show fully, as the chart shows. Our retatrutide half-life page has the detail, and how long retatrutide side effects last covers the timelines for the other effects.

What helped in trials, and what people try

The only published data on managing dysesthesia comes from the semaglutide 7.2 mg trials. Among 288 people who had it on that dose:

• 2% stopped treatment for good
• 8% paused treatment for a while
• 23% had their dose lowered

Most of the people who had one of those changes recovered, and the label says symptoms resolved faster when something was changed than when nothing was. Going back up is where it gets harder. Of 38 people who recovered and were stepped back up to 7.2 mg, 17 (45%) had it come back.

Lilly hasn't said how its trial doctors handled dysesthesia. Dose decisions belong with your prescriber, and our retatrutide dosage page shows the steps the trials used.

Our read: the only approach with data behind it is a dose change agreed with your prescriber.

No published trial has tested antihistamines, supplements or splitting the weekly dose into smaller shots as a fix for retatrutide skin symptoms. Loose clothing and lukewarm instead of hot showers haven't been tested either, but they cost nothing and carry little risk.

Rash, itching, acne and dry skin

Dysesthesia is a sensation in skin that looks normal. A reta rash or itchy skin is a different problem, and the evidence is thinner. In the Phase 2 obesity trial (table above), 7 of 267 people on retatrutide had a rash and 4 had itching, against none of the 70 on placebo. Spread across six dose groups, those counts are too small to rank.

None of Lilly's six Phase 3 results releases reports a rate for rash, itching, acne or dry skin. Acne and dry skin don't appear in either Phase 2 side effect table either, so neither reached 5% of any group. The Phase 2 diabetes trial, with 281 adults, listed no rash, itching or skin-sensation terms.

For allergy-type reactions, tirzepatide's label gives a sense of scale. In the Zepbound weight trials, reactions within a day of a dose affected 2.1% of people on the drug against 0.4% on placebo, and the label says most of the allergy-type reactions in its trials were skin reactions such as rash and itching. Severe ones were rare: 0.1%, against none on placebo. A red, itchy patch right where you injected is more likely an injection-site reaction; see our page on injection site reactions.

Where the vial came from matters too. No approved version of retatrutide exists yet, and anything sold online isn't Lilly's product. In an alert published in September 2026, Australia's TGA said a vial sold as retatrutide held no retatrutide at all, only undeclared semaglutide at about 8 times the level in approved products. The TGA and Australia's Chief Medical Officer have also reported severe allergic reactions linked to unapproved peptides. So a rash can come from what's in the vial rather than from retatrutide itself, and if you're looking at retatrutide for sale online, a batch-specific third-party test report is the minimum to ask for.

As for skin benefits, no trial has measured a skin outcome, so there's no evidence that retatrutide improves acne or the way skin looks. If your worry is thinning hair rather than skin, see retatrutide hair loss.

When skin symptoms need a doctor

See a doctor soon for any of these:

• Tingling or pain in one patch of skin, followed days later by a rash on one side of the body. The NHS says that's how shingles often starts, and it advises seeing a pharmacist within 3 days of the rash appearing.
• Numbness, pins and needles or burning pain in the feet or hands, or loss of balance or weakness. The NHS lists these as signs of nerve damage (peripheral neuropathy), which has causes that need checking.
• Yellow skin or eyes, dark urine or unusual bruising. In a June 2026 alert, Victoria's health department in Australia linked 6 cases of acute liver injury since January 2026 to unapproved products labeled retatrutide.
• Skin pain bad enough to stop you sleeping or wearing clothes, or that isn't easing after a few weeks.

Mention any skin symptom to your prescriber, even a mild one, before your next dose increase rather than after it. For the wider safety picture, see is retatrutide safe.